SEC
ACAD icon

Seven Eight Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Seven Eight Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-151,171
Closed -$2.8M – 669
2024
Q1 		$2.8M Buy
151,171
+84,964
+128% +$2.1M 0.29% 96
2023
Q4 		$2.07M Buy
66,207
+8,908
+16% +$213K 0.24% 117
2023
Q3 		$1.19M Buy
57,299
+3,575
+7% +$97.1K 0.14% 201
2023
Q2 		$1.29M Buy
+53,724
New +$1.19M 0.21% 154
2022
Q4 		– Sell
-26,935
Closed -$441K – 388
2022
Q3 		$441K Buy
+26,935
New +$436K 0.09% 306
2022
Q2 		– Sell
-10,923
Closed -$265K – 372
2022
Q1 		$265K Buy
+10,923
New +$264K 0.04% 435
2020
Q4 		– Sell
-5,258
Closed -$217K – 387
2020
Q3 		$217K Sell
5,258
-4,710
-47% -$203K 0.05% 508
2020
Q2 		$483K Buy
+9,968
New +$479K 0.35% 94
2020
Q1 		– Sell
-93,099
Closed -$3.98M – 439
2019
Q4 		$3.98M Sell
93,099
-44,370
-32% -$1.93M 0.21% 146
2019
Q3 		$4.95M Buy
137,469
+109,225
+387% +$3.31M 0.26% 111
2019
Q2 		$755K Buy
28,244
+20,300
+256% +$519K 0.04% 438
2019
Q1 		$213K Buy
+7,944
New +$186K 0.01% 523
2017
Q4 		– Sell
-35,403
Closed -$1.33M – 438
2017
Q3 		$1.33M Buy
+35,403
New +$1.15M 0.16% 202
2017
Q2 		– Sell
-294
Closed -$10K – 544
2017
Q1 		$10K Sell
294
-10,800
-97% -$381K ﹤0.01% 478
2016
Q4 		$320K Buy
+11,094
New +$294K 0.06% 346
2016
Q1 		– Sell
-14,400
Closed -$513K – 523
2015
Q4 		$513K Buy
14,400
+10,400
+260% +$366K 0.35% 95
2015
Q3 		$132K Buy
+4,000
New +$166K 0.11% 243
2015
Q1 		– Sell
-11,000
Closed -$349K – 481
2014
Q4 		$349K Buy
11,000
+7,400
+206% +$210K 0.58% 47
2014
Q3 		$89.1K Buy
+3,600
New +$84.2K 0.07% 345

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Seven Eight Capital's ACAD Position: Q2 2024 in Review

Seven Eight Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 151,171 shares — an estimated $2.8M sold.

Seven Eight Capital first reported a position in ACAD in Q3 2014 and held it in 19 quarters. The position peaked at $4.95M in Q3 2019. 265 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Seven Eight Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 151,171 Acadia Pharmaceuticals shares in Q2 2024, an estimated $2.8M.
  • Seven Eight Capital first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Seven Eight Capital's Acadia Pharmaceuticals position peaked at $4.95M in Q3 2019.
  • 265 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.